These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9081356)

  • 1. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay.
    Fernö M; Bendahl PO; Borg A; Brundell J; Hirschberg L; Olsson H; Killander D
    Eur J Cancer; 1996 May; 32A(5):793-801. PubMed ID: 9081356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.
    Malmström P; Bendahl PO; Boiesen P; Brünner N; Idvall I; Fernö M;
    J Clin Oncol; 2001 Apr; 19(7):2010-9. PubMed ID: 11283134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.
    Bouchet C; Spyratos F; Hacène K; Durcos L; Bécette V; Oglobine J
    Br J Cancer; 1998 May; 77(9):1495-501. PubMed ID: 9652768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
    Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.
    Broët P; Spyratos F; Romain S; Quillien V; Daver A; Ricolleau G; Rallet A; Toulas C; Asselain B
    Br J Cancer; 1999 May; 80(3-4):536-45. PubMed ID: 10408864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
    Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
    Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
    Schmitt M; Thomssen C; Ulm K; Seiderer A; Harbeck N; Höfler H; Jänicke F; Graeff H
    Br J Cancer; 1997; 76(3):306-11. PubMed ID: 9252196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
    Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
    Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
    Ferrero-Poüs M; Hacène K; Bouchet C; Le Doussal V; Tubiana-Hulin M; Spyratos F
    Clin Cancer Res; 2000 Dec; 6(12):4745-54. PubMed ID: 11156229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
    Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
    BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
    Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
    Br J Cancer; 1994 Feb; 69(2):398-405. PubMed ID: 8297742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
    Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
    J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N; Kates RE; Schmitt M
    J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Bontenbal M; Jänicke F; Klijn JG
    Cancer Res; 1992 Nov; 52(21):6101-5. PubMed ID: 1394237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
    Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
    Bull Cancer; 1994 Sep; 81(9):770-9. PubMed ID: 7703566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.